Quick Answer
Context Therapeutics Inc. reported Net Income of -$36.12 million for fiscal year 2025.
Context Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$36.12M -35.2% |
-$26.73M -11.5% |
-$23.96M -61.5% |
-$14.84M -41.9% |
-$10.46M -257.4% |
$6.64M |
| Diluted EPS | -$0.38 +17.4% |
-$0.46 +69.3% |
-$1.50 -61.3% |
-$0.93 +74.8% |
-$3.69 +6.8% |
-$3.96 |
| Total Assets | $68.49M -30.2% |
$98.13M +510.9% |
$16.06M -57.7% |
$37.97M -26.0% |
$51.31M +10878.2% |
$467.3K |
| Cash and Equivalents | $66.00M -30.1% |
$94.43M +553.5% |
$14.45M -59.3% |
$35.50M -28.5% |
$49.64M +16976.1% |
$290.7K |
| Stockholders Equity | $60.47M -36.5% |
$95.27M +702.5% |
$11.87M -65.8% |
$34.76M -28.0% |
$48.27M +385.3% |
-$16.92M +29.4% |
| Operating Income | -$39.70M -32.7% |
-$29.92M -19.3% |
-$25.07M -63.0% |
-$15.38M -46.1% |
-$10.53M -309.2% |
-$2.57M |
| Shares Outstanding | 91.88M +2.4% |
89.70M +461.8% |
15.97M +0.0% |
15.97M +0.0% |
15.97M +4712.1% |
331,789 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$9.69M | +44.5% | -9.8% |
| Diluted EPS | September 30, 2025 | -$0.10 | +54.5% | -11.1% |
| Total Assets | September 30, 2025 | $79.23M | -8.2% | -9.1% |
| Cash and Equivalents | September 30, 2025 | $76.94M | -9.3% | -7.9% |
| Stockholders Equity | September 30, 2025 | $73.17M | -12.7% | -11.4% |
| Operating Income | September 30, 2025 | -$10.61M | +43.3% | -8.7% |
| Shares Outstanding | September 30, 2025 | 91.88M | +22.5% | +2.4% |
- Context Therapeutics Inc. reported Net Income of -$36.12 million for fiscal year 2025.
- Context Therapeutics Inc. showed a decrease of -35.2% in Net Income compared to the prior fiscal year.
- Context Therapeutics Inc. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
- Context Therapeutics Inc. showed an increase of +17.4% in Diluted EPS compared to the prior fiscal year.
- Context Therapeutics Inc. reported Total Assets of $68.49 million for fiscal year 2025.
- Context Therapeutics Inc. showed a decrease of -30.2% in Total Assets compared to the prior fiscal year.
- Context Therapeutics Inc. reported Cash and Equivalents of $66.00 million for fiscal year 2025.
- Context Therapeutics Inc. showed a decrease of -30.1% in Cash and Equivalents compared to the prior fiscal year.
- Context Therapeutics Inc. reported Stockholders Equity of $60.47 million for fiscal year 2025.
- Context Therapeutics Inc. showed a decrease of -36.5% in Stockholders Equity compared to the prior fiscal year.
- Context Therapeutics Inc. reported Operating Income of -$39.70 million for fiscal year 2025.
- Context Therapeutics Inc. showed a decrease of -32.7% in Operating Income compared to the prior fiscal year.
- Context Therapeutics Inc. reported Shares Outstanding of 91.88 million shares for fiscal year 2025.
- Context Therapeutics Inc. showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: